{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T23:48:44Z","timestamp":1785887324201,"version":"3.56.0"},"reference-count":58,"publisher":"American Society for Microbiology","issue":"11","license":[{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2025,11,5]]},"abstract":"ABSTRACT<\/jats:title>\n \n \n \n We aimed to develop a population pharmacokinetic model of cefazolin in children undergoing maintenance hemodialysis for kidney failure and simulate dosing regimens to optimize patients\u2019 exposure. Cefazolin plasma concentrations were quantified using high-performance liquid chromatography. A non-linear mixed-effect modeling approach was used to investigate cefazolin pharmacokinetics. Optimal dosing regimens were determined using Monte Carlo simulations targeting 100% of the time a free plasma concentration four times above the minimum inhibitory concentration (MIC) and total plasma concentration less than 80 mg\/L (100% fT > 4 \u00d7 MIC and\n C<\/jats:italic>\n < 80 mg\/L). Eighty-three samples were analyzed from six patients aged 1.3\u201314.6 years and weighing 11.4\u201351 kg. A one-compartment model with first-order elimination best fitted the data, with a significant between-subject variability (BSV). Body weight (BW), using the allometric rule, was a significant predictor of residual elimination clearance (CL) and volume of distribution (Vd), while dialysis membrane surface area (DMSA) explained almost all the BSV on dialysis clearance (CLdial). The parameter relationships were Vd\n \n i<\/jats:italic>\n <\/jats:sub>\n (L) = 14.6 \u00d7 (BW\n \n i<\/jats:sub>\n <\/jats:italic>\n \/70), CL\n i<\/jats:sub>\n (L\/h) = 0.186 \u00d7 (BW\n \n i<\/jats:sub>\n <\/jats:italic>\n \/70)\n 0.75<\/jats:sup>\n , CLdial\n \n i<\/jats:italic>\n <\/jats:sub>\n (L\/h)=1.98 \u00d7 (DMSA\n \n i<\/jats:sub>\n <\/jats:italic>\n \/1)\n 1.26<\/jats:sup>\n , CLtot\n i<\/jats:sub>\n = CL\n \n i<\/jats:sub>\n +\n <\/jats:italic>\n CLdial\n DMSA<\/jats:sub>\n \n i<\/jats:sub>\n <\/jats:italic>\n , where the subscript\n i<\/jats:italic>\n denotes the\n i<\/jats:italic>\n th<\/jats:sup>\n patient\u2019s covariate value. Dosing regimens were simulated for six CL ranges, targeting two concentration intervals: 40\u201380 mg\/L and 20\u201380 mg\/L for MIC of 2 and 1 mg\/L, respectively. In children on maintenance hemodialysis for kidney failure, due to the persistence of a large unexplained BSV on CL that substantially affects them, optimal dosing regimen would not be accurately determined a priori and should be individually determined using therapeutic drug monitoring, taking BW, DMSA, and CL into account.\n <\/jats:p>\n \n CLINICAL TRIALS<\/jats:title>\n \n This study is registered with ClinicalTrials.gov as\n NCT02539407<\/jats:related-object>\n .\n <\/jats:p>\n <\/jats:sec>\n <\/jats:sec>","DOI":"10.1128\/aac.00451-25","type":"journal-article","created":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T13:01:42Z","timestamp":1759410102000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":1,"title":["Cefazolin population pharmacokinetics in children undergoing maintenance hemodialysis for kidney failure"],"prefix":"10.1128","volume":"69","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0165-7947","authenticated-orcid":true,"given":"Romain","family":"Berthaud","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05f82e368","id-type":"ROR","asserted-by":"publisher"}],"name":"Universit\u00e9 Paris Cit\u00e9, INSERM, Pharmacologie et Evaluations des Th\u00e9rapeutiques chez l'Enfant et la Femme Enceinte","place":["Paris, France"]},{"id":[{"id":"https:\/\/ror.org\/05tr67282","id-type":"ROR","asserted-by":"publisher"}],"name":"Centre d\u2019Investigation Clinique 1419, Inserm, AP-HP, H\u00f4pital Necker-Enfants Malades","place":["Paris, France"]},{"id":[{"id":"https:\/\/ror.org\/05tr67282","id-type":"ROR","asserted-by":"publisher"}],"name":"Service de N\u00e9phrologie P\u00e9diatrique, AP-HPH, H\u00f4pital Necker-Enfants Malades","place":["Paris, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sa\u00efk","family":"Urien","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05f82e368","id-type":"ROR","asserted-by":"publisher"}],"name":"Universit\u00e9 Paris Cit\u00e9, INSERM, Pharmacologie et Evaluations des Th\u00e9rapeutiques chez l'Enfant et la Femme Enceinte","place":["Paris, France"]},{"name":"Unit\u00e9 de Recherche Clinique Necker Cochin, AP-HP, H\u00f4pital Tarnier","place":["Paris, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saoussen","family":"Krid","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05tr67282","id-type":"ROR","asserted-by":"publisher"}],"name":"Service de N\u00e9phrologie P\u00e9diatrique, AP-HPH, H\u00f4pital Necker-Enfants Malades","place":["Paris, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frantz","family":"Foissac","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05f82e368","id-type":"ROR","asserted-by":"publisher"}],"name":"Universit\u00e9 Paris Cit\u00e9, INSERM, Pharmacologie et Evaluations des Th\u00e9rapeutiques chez l'Enfant et la Femme Enceinte","place":["Paris, France"]},{"name":"Unit\u00e9 de Recherche Clinique Necker Cochin, AP-HP, H\u00f4pital Tarnier","place":["Paris, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Oualha","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05f82e368","id-type":"ROR","asserted-by":"publisher"}],"name":"Universit\u00e9 Paris Cit\u00e9, INSERM, Pharmacologie et Evaluations des Th\u00e9rapeutiques chez l'Enfant et la Femme Enceinte","place":["Paris, France"]},{"id":[{"id":"https:\/\/ror.org\/05tr67282","id-type":"ROR","asserted-by":"publisher"}],"name":"Unit\u00e9 de R\u00e9animation et Surveillance Continue P\u00e9diatrique, AP-HP, H\u00f4pital Necker-Enfants Malades","place":["Paris, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micha\u00ebl","family":"Thy","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05f82e368","id-type":"ROR","asserted-by":"publisher"}],"name":"Universit\u00e9 Paris Cit\u00e9, INSERM, Pharmacologie et Evaluations des Th\u00e9rapeutiques chez l'Enfant et la Femme Enceinte","place":["Paris, France"]},{"id":[{"id":"https:\/\/ror.org\/02vjkv261","id-type":"ROR","asserted-by":"publisher"}],"name":"Universit\u00e9 Sorbonne Paris Nord, INSERM, UMR1137 IAME","place":["Paris, France"]},{"id":[{"id":"https:\/\/ror.org\/03fdnmv92","id-type":"ROR","asserted-by":"publisher"}],"name":"Unit\u00e9 de R\u00e9animation, AP-HP, H\u00f4pital Bich\u00e2t Claude-Bernard","place":["Paris, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Boyer","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05tr67282","id-type":"ROR","asserted-by":"publisher"}],"name":"Service de N\u00e9phrologie P\u00e9diatrique, AP-HPH, H\u00f4pital Necker-Enfants Malades","place":["Paris, France"]},{"id":[{"id":"https:\/\/ror.org\/05f82e368","id-type":"ROR","asserted-by":"publisher"}],"name":"Universit\u00e9 Paris Cit\u00e9, INSERM, U1163 Institut Imagine","place":["Paris, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agathe","family":"B\u00e9ranger","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05f82e368","id-type":"ROR","asserted-by":"publisher"}],"name":"Universit\u00e9 Paris Cit\u00e9, INSERM, Pharmacologie et Evaluations des Th\u00e9rapeutiques chez l'Enfant et la Femme Enceinte","place":["Paris, France"]},{"id":[{"id":"https:\/\/ror.org\/05tr67282","id-type":"ROR","asserted-by":"publisher"}],"name":"Unit\u00e9 de R\u00e9animation et Surveillance Continue P\u00e9diatrique, AP-HP, H\u00f4pital Necker-Enfants Malades","place":["Paris, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9898-2609","authenticated-orcid":true,"given":"D\u00e9borah","family":"Hirt","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05f82e368","id-type":"ROR","asserted-by":"publisher"}],"name":"Universit\u00e9 Paris Cit\u00e9, INSERM, Pharmacologie et Evaluations des Th\u00e9rapeutiques chez l'Enfant et la Femme Enceinte","place":["Paris, France"]},{"id":[{"id":"https:\/\/ror.org\/00ph8tk69","id-type":"ROR","asserted-by":"publisher"}],"name":"D\u00e9partement de Pharmacologie, AP-HP, H\u00f4pital Cochin","place":["Paris, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sihem","family":"Benaboud","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05f82e368","id-type":"ROR","asserted-by":"publisher"}],"name":"Universit\u00e9 Paris Cit\u00e9, INSERM, Pharmacologie et Evaluations des Th\u00e9rapeutiques chez l'Enfant et la Femme Enceinte","place":["Paris, France"]},{"id":[{"id":"https:\/\/ror.org\/00ph8tk69","id-type":"ROR","asserted-by":"publisher"}],"name":"D\u00e9partement de Pharmacologie, AP-HP, H\u00f4pital Cochin","place":["Paris, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Marc","family":"Tr\u00e9luyer","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05f82e368","id-type":"ROR","asserted-by":"publisher"}],"name":"Universit\u00e9 Paris Cit\u00e9, INSERM, Pharmacologie et Evaluations des Th\u00e9rapeutiques chez l'Enfant et la Femme Enceinte","place":["Paris, France"]},{"id":[{"id":"https:\/\/ror.org\/05tr67282","id-type":"ROR","asserted-by":"publisher"}],"name":"Centre d\u2019Investigation Clinique 1419, Inserm, AP-HP, H\u00f4pital Necker-Enfants Malades","place":["Paris, France"]},{"name":"Unit\u00e9 de Recherche Clinique Necker Cochin, AP-HP, H\u00f4pital Tarnier","place":["Paris, France"]},{"id":[{"id":"https:\/\/ror.org\/00ph8tk69","id-type":"ROR","asserted-by":"publisher"}],"name":"D\u00e9partement de Pharmacologie, AP-HP, H\u00f4pital Cochin","place":["Paris, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na\u00efm","family":"Bouazza","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05f82e368","id-type":"ROR","asserted-by":"publisher"}],"name":"Universit\u00e9 Paris Cit\u00e9, INSERM, Pharmacologie et Evaluations des Th\u00e9rapeutiques chez l'Enfant et la Femme Enceinte","place":["Paris, France"]},{"name":"Unit\u00e9 de Recherche Clinique Necker Cochin, AP-HP, H\u00f4pital Tarnier","place":["Paris, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(88)90044-5"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2000.00337.x"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfv007"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2023.03.018"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.V95869"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1542-4758.2006.01175.x"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2021.06.018"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.11411116"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.01590309"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/s150100070005"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/QCO.0000000000000752"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-004-1596-8"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2019.02.014"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2018.07.093"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2021.11.008"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-11-279"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ308"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12941-016-0143-3"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1086\/510386"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2012010050"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1053\/ajkd.1998.v32.pm9740155"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2019.03.010"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1086\/599376"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/bja\/aew032"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw496"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2020.04.022"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.05150418"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.8.1.63"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt1974154344"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/128.supplement_2.s347"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1159\/000184077"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1159\/000184077"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/13.4.772"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-017-0578-2"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410170221"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-019-2378-9"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt1976196825"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0022-3476(80)80842-0"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1177\/009127007701700406"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/128.supplement_2.s358"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.1053\/ajkd.1998.v32.pm9740156"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-1960"},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.3791\/58148"},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00863-15"},{"key":"e_1_3_4_46_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pharmtox.48.113006.094708"},{"key":"e_1_3_4_47_2","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-011-9255-z"},{"key":"e_1_3_4_48_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky574"},{"key":"e_1_3_4_49_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1785"},{"key":"e_1_3_4_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0272-6386(01)80126-8"},{"key":"e_1_3_4_51_2","doi-asserted-by":"publisher","DOI":"10.1177\/1060028018809695"},{"key":"e_1_3_4_52_2","doi-asserted-by":"publisher","DOI":"10.1213\/ANE.0000000000003876"},{"key":"e_1_3_4_53_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.28.8.977"},{"key":"e_1_3_4_54_2","doi-asserted-by":"publisher","DOI":"10.3339\/jkspn.2020.24.2.69"},{"key":"e_1_3_4_55_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-020-04821-y"},{"key":"e_1_3_4_56_2","doi-asserted-by":"publisher","DOI":"10.3345\/cep.2022.01431"},{"key":"e_1_3_4_57_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2023.10.018"},{"key":"e_1_3_4_58_2","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.16224"},{"key":"e_1_3_4_59_2","unstructured":"2024. R\u00e9sum\u00e9 Des Caract\u00e9ristiques Du Produit - CEFAZOLINE VIATRIS 1 g Poudre Pour Solution Injectable (IM-IV) - Base de Donn\u00e9es Publique Des M\u00e9dicaments. Available from: https:\/\/base donneespublique.medicaments.gouv.fr\/affichageDoc.php?specid=61242331&typedoc=R"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.00451-25","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.00451-25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T23:07:11Z","timestamp":1785884831000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/aac.00451-25"}},"subtitle":[],"editor":[{"given":"James E.","family":"Leggett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,11,5]]},"references-count":58,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11,5]]}},"alternative-id":["10.1128\/aac.00451-25"],"URL":"https:\/\/doi.org\/10.1128\/aac.00451-25","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,5]]},"assertion":[{"value":"2025-03-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-30","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00451-25"}}